GSK Confident Its ‘Last Drug Standing’ In Anemia Class Can Gain US Panel Backing
Safety Profile Will Be Closely Scrutinized
Executive Summary
GSK could have the US market to itself if it can convince the expert panel of daprodustat’s safety, as rivals have fallen by the wayside.